The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

This is a multi-center, randomized, open-label trial through Peking University People's Hospital investigating how the combination of oral all-trans retinoic acid (ATRA) and high-dose dexamethasone vs high-dose dexamethasone alone as first-line treatment immune thrombocytopenia. Eligibility is restricted to adult patients between 18-70 years of age who have newly diagnosed ITP, and a platelet count under 30 x 109/L OR significant bleeding and a platelet count less than 50 x 109/L.

China

https://clinicaltrials.gov/ct2/show/NCT04217148?recrs=a&cond=Immune+Thrombocytopenia&draw=2&rank=5

Recruiting

back to top

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo